The risk ratio(RR = 0.70, 95%CI 0.62–0.80, P<0.00001) estimated by a fixed-effects model demonstrated a lower rate of 3-year OS in the HER3-positive GC patients than in the HER3-negative GC patients (Fig 3A). Here, ERBB3 is linked to gastric cancer.